Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Retained Earnings (2020 - 2023)

Terns Pharmaceuticals' Retained Earnings history spans 4 years, with the latest figure at -$311.6 million for Q3 2023.

  • For Q3 2023, Retained Earnings fell 37.52% year-over-year to -$311.6 million; the TTM value through Sep 2023 reached -$311.6 million, down 37.52%, while the annual FY2022 figure was -$822000.0, 143.2% down from the prior year.
  • Retained Earnings reached -$311.6 million in Q3 2023 per TERN's latest filing, down from -$775000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$124000.0 in Q4 2020 to a low of -$311.6 million in Q3 2023.
  • Average Retained Earnings over 4 years is -$61.5 million, with a median of -$595500.0 recorded in 2023.
  • Peak YoY movement for Retained Earnings: tumbled 135586.23% in 2022, then surged 99.79% in 2023.
  • A 4-year view of Retained Earnings shows it stood at -$124000.0 in 2020, then tumbled by 172.58% to -$338000.0 in 2021, then tumbled by 143.2% to -$822000.0 in 2022, then tumbled by 37808.64% to -$311.6 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Retained Earnings are -$311.6 million (Q3 2023), -$775000.0 (Q2 2023), and -$416000.0 (Q1 2023).